![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
German chemical and pharmaceuticals group Bayer AG said Tuesday the U.S. Food & Drug Administration has granted a priority review of nexavar for the treatment of differentiated thyroid cancer.
MAIN FACTS:
-Bayer collaborates with Onyx Pharmaceuticals (ONXX) in the U.S. on its nexavar drug, also known as sorafenib.
-The FDA grants priority reviews to medicines with the potential to significantly improve serious conditions.
-The FDA aims to complete the review within six months, rather than the standard 10 months, Bayer said.
-The decision was based on Phase III trial data showing the drug significantly extended progression-free survival.
-Thyroid cancer is the sixth most common cancer in women, and 35,000 patients in the world succumb to the disease annually.
-The drug is an oral anti-cancer therapy for liver cancer and advanced kidney cancer.
-"Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of other cancers," Bayer said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions